drugset / Trial / NCT03043521

Pharmacodynamic Properties of CJ-12420 on Evening Dosing

NCT03043521

Phase 1 Completed 24 enrolled HK inno.N Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare and evaluate impact on pharmacodynamic characteristics of CJ-12420 and dexlansoprazole with evening dosing in healthy male volunteers

Timeline

Start
2015-05-13
Primary completion
2015-08-12
Completion
2015-08-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexlansoprazole Other / unclassified 60 mg
Subject Tegoprazan Other / unclassified 50 mg
Subject Tegoprazan Other / unclassified 100 mg
Subject Tegoprazan Other / unclassified 200 mg

Indications

No indication recorded.